An alliance of drugmakers, philanthropists and governments are targeting neglected diseases such as malaria and tuberculosis that infect millions of people every year in low-income countries with little ability to pay for treatments. In addition to GlaxoSmithKline's Drugs for the Developing World center, AstraZeneca, Novartis and other drugmakers have joined several such alliances.

Related Summaries